MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

Search

SCYNEXIS Inc

Fermé

0.83 -6.74

Résumé

Variation du prix de l'action

24h

Actuel

Min

0.81

Max

0.9

Chiffres clés

By Trading Economics

Revenu

-1.6M

-4.4M

Ventes

317K

977K

BPA

-0.09

Marge bénéficiaire

-453.736

Employés

28

EBITDA

-1.2M

-4.2M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+400% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

1.5M

38M

Ouverture précédente

7.57

Clôture précédente

0.83

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

SCYNEXIS Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

4 avr. 2025, 22:38 UTC

Actions en Tendance

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

4 avr. 2025, 21:53 UTC

Market Talk

Maxeon's Supply Chain Move at Critical Time for Solar Panel Cos -- Market Talk

4 avr. 2025, 21:44 UTC

Actualités
Acquisitions, Fusions, Rachats

Trump Grants 75-Day Extension to Reach TikTok Deal -- 3rd Update

4 avr. 2025, 21:00 UTC

Actualités

Americans Were Souring on Trump's Economic Plans Even Before Tariff Bloodbath -- WSJ

4 avr. 2025, 20:52 UTC

Market Talk

Peloton Likely to Escape Tariffs Unscathed -- Market Talk

4 avr. 2025, 20:52 UTC

Actualités

Trump Can Cut Teacher-Training Programs For Now, Supreme Court Says -- WSJ

4 avr. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 avr. 2025, 20:48 UTC

Actualités

The Score: Nike, Apple, Stellantis and More Stocks That Defined the Week -- WSJ

4 avr. 2025, 20:45 UTC

Actualités

Hiring Defied Expectations in March, With 228,000 New Jobs -- 6th Update

4 avr. 2025, 20:32 UTC

Actualités

Dow Tumbles 2,000 Points, Bonds Rally After China Retaliates Against Trump Tariffs -- WSJ

4 avr. 2025, 20:21 UTC

Actualités

China Hits Back at Trump With Sweeping Tariffs on All U.S. Goods -- Update

4 avr. 2025, 20:00 UTC

Actualités

Republicans March Ahead on Trump's Tax Cuts as Tariffs Kick In -- WSJ

4 avr. 2025, 19:51 UTC

Market Talk

Dollar Recovers While Recession Fears Grip Wall Street -- Market Talk

4 avr. 2025, 19:37 UTC

Actualités

Trump's Team is Getting the Bond Rally It Wanted. But for the Wrong Reasons. -- WSJ

4 avr. 2025, 19:32 UTC

Market Talk

Oil Selloff Continues as China Responds to U.S. Tariffs -- Market Talk

4 avr. 2025, 19:28 UTC

Actualités

U.S. Stocks Fall Further After China Retaliates Against Trump Tariffs -- Update

4 avr. 2025, 19:15 UTC

Market Talk

Costco Gold, Membership Fees Could Help Cushion from Tariff Costs -- Market Talk

4 avr. 2025, 19:12 UTC

Actualités

Powell Warns of Higher Prices, Weaker Growth After Tariff Plan -- 3rd Update

4 avr. 2025, 19:11 UTC

Market Talk

U.S. Natural Gas Falls as Global Selloff Continues -- Market Talk

4 avr. 2025, 19:09 UTC

Market Talk

Mexican Stocks, Peso Tumble as Global Rout Continues -- Market Talk

4 avr. 2025, 19:09 UTC

Actualités

Trump Grants 75-Day Extension to Reach TikTok Deal -- Second Update

4 avr. 2025, 19:00 UTC

Market Talk

Fed Has Limited Options to Counter Tariffs -- Market Talk

4 avr. 2025, 18:53 UTC

Market Talk

Brace for Trump's Tariff Order to Remain in Place for Extended Period -- Market Talk

4 avr. 2025, 18:51 UTC

Market Talk

Morgan Stanley Analysts Outline Paths to Recession -- Market Talk

4 avr. 2025, 18:44 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

4 avr. 2025, 18:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 avr. 2025, 18:44 UTC

Market Talk

Tariffs Won't Achieve What Trump Wants, Morgan Stanley Says -- Market Talk

4 avr. 2025, 18:43 UTC

Acquisitions, Fusions, Rachats

Trump Extends Deadline for TikTok Ban Another 75 Days. ByteDance Says 'An Agreement Has Not Been Executed.' -- Barrons.com

4 avr. 2025, 18:43 UTC

Acquisitions, Fusions, Rachats

Trump Extends TikTok Ban Deadline A Second Time As Deal Chatter Swirls -- IBD

4 avr. 2025, 18:39 UTC

Market Talk

Protectionism is Back, And Recession Could Follow, Morgan Stanley Says -- Market Talk

Comparaison

Variation de prix

SCYNEXIS Inc prévision

Objectif de Prix

By TipRanks

400% hausse

Prévisions sur 12 Mois

Moyen 4.5 USD  400%

Haut 5 USD

Bas 4 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

2

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

N/A / 1.04Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

No Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos SCYNEXIS Inc

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.